Acadia Healthcare
ACHC
$23.02
-4.36%
Acadia Healthcare Company, Inc. is a specialized behavioral healthcare provider that acquires and develops facilities offering acute inpatient psychiatric care, specialty treatment, and residential services. The company is a significant player in the fragmented U.S. behavioral health market, operating a large network of facilities and positioning itself as a consolidator within the industry. The current investor narrative is dominated by deep concerns over its financial health and turnaround prospects, as highlighted by a major fund's complete exit from its stake, casting a shadow over the stock's recent price recovery and raising questions about the sustainability of its operational improvements.…
ACHC
Acadia Healthcare
$23.02
Related headlines
Investment Opinion: Should I buy ACHC Today?
Rating: Hold. The thesis is that ACHC presents a speculative turnaround opportunity with compelling valuation upside, but the severe fundamental risks and lack of a clear profitability catalyst warrant extreme caution, making it suitable only for risk-tolerant investors with a high conviction in management's execution.
Supporting evidence includes the deeply discounted Price-to-Sales ratio of 0.39x, which is low for a healthcare facilities company. The forward P/E of 16.24x, based on analyst EPS estimates of $1.83, suggests the market is pricing in a successful recovery. The stock's powerful 3-month momentum of +107% and its trading near the 52-week high indicate strong near-term sentiment. However, this is counterbalanced by the catastrophic ROE of -56.58% and negative trailing net margin of -33.29%.
The biggest risks are the persistence of net losses, the high financial leverage (D/E of 1.36), and the loss of institutional confidence as evidenced by the major fund's exit. This Hold rating would upgrade to a Buy if the company reports quarterly EPS consistent with the $1.83 annualized run-rate and demonstrates sequential margin improvement. It would downgrade to a Sell if quarterly results show no progress toward profitability or if debt levels increase. Based on the current data, the stock appears fairly valued for the high risk it embodies, trading at a discount on sales but a premium on forward earnings expectations that are not yet proven.
Sign up to view all
ACHC 12-Month Price Forecast
ACHC is a high-stakes bet on a corporate turnaround that is showing promising price action but lacks confirming fundamental evidence. The AI assessment is neutral due to the offsetting forces of deep value and severe operational risk. Confidence is medium because the key variables—profitability and debt management—are within management's control but have a poor recent track record. The stance would upgrade to bullish on confirmation of sustained quarterly profitability and a reduction in leverage. It would downgrade to bearish on a breakdown below key technical support at $22 or a widening of net losses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Acadia Healthcare's 12-month outlook, with a consensus price target around $29.93 and implied upside of +30.0% versus the current price.
Average Target
$29.93
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$18 - $30
Analyst target range
Analyst coverage for Acadia Healthcare is limited, with only 3 analysts providing estimates, indicating this is a stock with lower institutional research visibility which can contribute to higher volatility and less efficient price discovery. The consensus focuses on forward estimates, projecting an average EPS of $1.83 on revenue of approximately $4.20 billion, but a specific consensus price target, recommendation, and target range are not provided in the data. The absence of explicit price targets and the wide discrepancy between the negative trailing fundamentals and positive forward estimates highlighted by the analysts signal high uncertainty and a binary investment case centered on the company's ability to execute a successful turnaround and return to sustained profitability as forecasted.
Bulls vs Bears: ACHC Investment Factors
The investment case for ACHC is a classic high-risk, high-reward turnaround story. The bull side is supported by a powerful technical reversal from extreme lows and a deeply discounted valuation that prices in significant distress. However, the bear case is anchored in severe and persistent profitability issues, evidenced by catastrophic ROE and negative net margins, compounded by a major institutional vote of no confidence. Currently, the bear side holds stronger fundamental evidence due to the concrete, alarming financial metrics, while the bull case relies heavily on future expectations and technical momentum. The single most important tension is whether the company can achieve the analyst-projected EPS of $1.83 to justify its forward P/E of 16x, or if the current operational losses and high leverage will lead to further financial deterioration.
Bullish
- Massive Technical Reversal: The stock has surged 107.22% over the past 3 months from a deeply oversold 52-week low of $11.43, decisively breaking its prior downtrend. This explosive momentum, with a 1-month relative strength of +7.68% vs. the SPY, signals a powerful shift in market sentiment and potential for a continued short squeeze given the high short ratio of 8.05.
- Deeply Discounted Valuation: ACHC trades at a Price-to-Sales ratio of just 0.39x and an EV/Sales of 1.50x, indicating the market is assigning a significant discount to its $4.2 billion revenue base. This low multiple provides a margin of safety and substantial upside potential if the company can demonstrate a credible path to profitability.
- Market Expects Profitability Return: Despite a trailing EPS of -$0.86, the forward P/E of 16.24x implies the market is pricing in a significant earnings recovery, with analysts projecting forward EPS of $1.83. The positive operating margin of 11.71% shows the core business is profitable before financial costs, supporting the turnaround thesis.
- Strong Operational Momentum: The stock's year-to-date gain of 94.89% and its current price near the 52-week high of $28.57 demonstrate powerful buying pressure. With a beta of 0.71, this rally has occurred with historically lower volatility than the market, suggesting the move may be driven by fundamental re-rating rather than speculative frenzy.
Bearish
- Severe Profitability Crisis: The company is deeply unprofitable with a net margin of -33.29% and a devastating Return on Equity of -56.58%. This reflects significant financial leverage (Debt/Equity of 1.36) eroding shareholder value, casting serious doubt on the sustainability of the business model without a dramatic turnaround.
- Major Institutional Exit: Recent news highlights a major fund's complete exit from a $13 million stake, signaling deep institutional concern over the company's financial health and turnaround prospects. This exit occurred despite the stock's recent recovery, suggesting informed sellers see fundamental weakness persisting.
- Thin Margins and High Leverage: A gross margin of only 17.61% leaves little room for error, while the debt-to-equity ratio of 1.36 indicates significant financial risk. The negative EV/EBITDA of -5.16 further confirms that the company's earnings before interest, taxes, depreciation, and amortization are insufficient to cover its capital structure.
- Limited Analyst Coverage & High Uncertainty: With only 3 analysts providing estimates, there is low institutional research visibility, which can lead to higher volatility and less efficient price discovery. The absence of explicit consensus price targets underscores the high uncertainty and binary nature of the investment case centered on an unproven turnaround.
ACHC Technical Analysis
The stock is in a powerful recovery phase from deeply oversold levels, with a 1-year price change of +22.26% and a staggering 3-month surge of +107.22%. As of the latest close at $27.85, the price is trading at approximately 97% of its 52-week high of $28.57, indicating it is testing a critical resistance level after a massive rally; this positioning near the highs suggests strong momentum but also raises risks of a technical pullback or consolidation. Recent momentum is exceptionally strong, with a 1-month gain of +17.66% and a 3-month gain of +107.22%, far outpacing the SPY's respective gains of +9.98% and +4.14%; this sharp acceleration from a low base in January 2026 signals a decisive reversal from the prior downtrend, though the extreme short-term move warrants caution. Key technical support is at the 52-week low of $11.43, while immediate resistance is the 52-week high of $28.57; a confirmed breakout above $28.57 could signal a new bullish phase, while a failure here may lead to a retracement. The stock's beta of 0.71 indicates it has been less volatile than the broader market historically, but the recent explosive price action and a high short ratio of 8.05 suggest elevated near-term volatility and potential for a short squeeze.
Beta
0.73
0.73x market volatility
Max Drawdown
-57.1%
Largest decline past year
52-Week Range
$11-$30
Price range past year
Annual Return
-2.1%
Cumulative gain past year
| Period | ACHC Return | S&P 500 |
|---|---|---|
| 1m | -16.1% | +5.5% |
| 3m | +37.1% | +7.7% |
| 6m | +51.6% | +12.7% |
| 1y | -2.1% | +27.4% |
| ytd | +61.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ACHC Fundamental Analysis
Revenue trajectory analysis is constrained as specific quarterly revenue and growth rate data are not available in the provided dataset; however, analyst estimates project full-year revenue of approximately $4.20 billion, providing a forward-looking benchmark for the company's scale. The company is currently unprofitable on a net income basis, with a trailing EPS of -$0.86 and a negative net margin of -33.29%; however, the forward P/E of 16.24x implies the market expects a return to profitability, with an estimated EPS of $1.83. Gross margin stands at a relatively thin 17.61%, while the operating margin is 11.71%, indicating the core operations are generating a profit before interest and taxes, but significant financial leverage or other costs are dragging down the bottom line. The balance sheet shows moderate financial leverage with a debt-to-equity ratio of 1.36, and reasonable liquidity with a current ratio of 1.55. The negative Return on Equity (ROE) of -56.58% is a major red flag, reflecting the net loss and high leverage eroding shareholder value, though the positive Return on Assets (ROA) of 4.20% suggests the company's assets are generating some operational return. Free cash flow data is not available, but the price-to-cash-flow ratio of 9.76 suggests the market is valuing the company's cash generation at a moderate multiple.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ACHC Overvalued?
Given the negative trailing net income and EPS, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.39x and an Enterprise Value-to-Sales (EV/Sales) of 1.50x, which are low multiples suggesting the market is assigning a discounted valuation relative to its revenue base, likely due to profitability concerns. Peer comparison data for industry averages is not available in the provided dataset, preventing a direct sector premium/discount analysis; however, the low absolute PS and EV/Sales multiples typically indicate a value-oriented valuation in the healthcare facilities sector, pending profitability improvement. Historical valuation context is also unavailable due to missing historical ratios data, making it impossible to determine if the current PS ratio is near its own historical highs or lows; this lack of historical benchmark limits the ability to assess whether current levels represent a cyclical opportunity or reflect a persistent fundamental discount.
PE
-1.2x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-5.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on profitability. The company's net margin of -33.29% and ROE of -56.58% indicate a fundamental crisis where operations are destroying shareholder value. With a debt-to-equity ratio of 1.36, the company is leveraged, and its thin 17.61% gross margin provides minimal cushion against cost pressures or reimbursement rate changes. The path to achieving the forward EPS of $1.83 is fraught with execution risk, and any stumble could lead to further losses and balance sheet stress.
Market & Competitive Risks include valuation compression if the turnaround narrative falters. The stock has already rallied 107% in 3 months to test its 52-week high, leaving little room for disappointment. Its low beta of 0.71 suggests it is less correlated to market swings, but the high short ratio of 8.05 indicates a skeptical investor base that could amplify selling on negative news. The behavioral healthcare sector is fragmented and competitive, and ACHC's reliance on a consolidator strategy is capital-intensive and risky in a higher interest rate environment.
Worst-Case Scenario involves a failure of the turnaround, leading to a loss of investor confidence, analyst downgrades, and a revisit of recent lows. The specific chain would be a Q3 earnings miss versus the $1.83 EPS estimate, triggering the high short interest to cover profits and long-term holders to exit. This could realistically push the stock back toward its 52-week low of $11.43, representing a downside of approximately -59% from the current price of $27.85. The historical max drawdown of -61.48% shows the stock is capable of such severe declines.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The company is burning through shareholder equity, evidenced by a -56.58% ROE and negative net margins, exacerbated by a debt-to-equity ratio of 1.36. 2) Execution Risk: The entire investment thesis hinges on achieving a dramatic turnaround to $1.83 EPS from a current loss, with no margin for error given thin 17.61% gross margins. 3) Sentiment Risk: A major fund recently exited its entire stake, signaling a lack of institutional confidence that could be contagious. 4) Volatility Risk: A high short ratio of 8.05 and recent explosive price moves indicate the potential for sharp declines on any negative news.
The 12-month forecast is highly bifurcated. The base case (50% probability) sees the stock consolidating between $24 and $28 as it works to prove its turnaround. The bull case (25% probability), catalyzed by successful earnings, projects a breakout toward $32-$38. The bear case (25% probability), triggered by operational deterioration, foresees a collapse back toward the $11-$16 range. The most likely scenario is the base case, as it reflects the high uncertainty and the time required to validate the earnings recovery currently priced into the forward P/E of 16.24x.
ACHC presents a paradoxical valuation: it is deeply undervalued on a sales basis (PS 0.39x) but appears to be pricing in significant future growth on an earnings basis (forward P/E 16.24x). Compared to its own revenue base, the stock is cheap. However, this discount reflects the market's justified skepticism given the current net losses. The valuation implies the market expects a successful turnaround to profitability. Until that is proven, the stock is fairly valued for its high-risk profile, not clearly overvalued or undervalued.
ACHC is a high-risk, high-potential-reward stock that may be a good buy only for speculative investors with a strong stomach for volatility. The compelling factors are its deeply discounted valuation (PS ratio 0.39x) and powerful 3-month momentum of +107%. However, it is a terrible buy for conservative or income-seeking investors due to its severe profitability crisis (ROE -56.58%), lack of dividend, and high uncertainty. A purchase should be predicated on a firm belief that management can deliver on the analyst forecast of $1.83 EPS.
ACHC is not suitable for short-term trading due to its binary nature and potential for gap moves on earnings news, despite its recent momentum. It is a speculative long-term investment for investors willing to hold for 2-3 years to see if the turnaround narrative fully plays out or definitively fails. The low beta of 0.71 suggests it is not a tactical market-timing tool. Given the lack of dividends and the focus on capital appreciation from a successful operational restructuring, a minimum holding period of 12-18 months is suggested to allow for several quarterly reports to provide clarity.